Searching happens on your device — what you type here never leaves your browser.

conditions 18 min read · August 25, 2026

Eczema in Black Skin

What You Need to Know

Eczema often looks and behaves differently on our skin than the textbooks suggest, and that gap shapes how it gets diagnosed, or misdiagnosed, and treated. Atopic dermatitis, commonly called eczema, is a chronic condition in which the skin's protective barrier is weaker than it should be. Moisture escapes more easily, and irritants, allergens, and bacteria get in more easily too, creating a cycle of dryness, inflammation, and itching that can flare and fade for years, and it often persists well into adulthood rather than resolving in childhood 1.

Understanding how eczema shows up on us specifically is where real, practical care starts. This guide is written for Black women who want to understand what eczema is, what it can look like on our skin specifically, what is driving it, and what the evidence, including evidence on people who look like us, says about treatment.

START HERE: WHAT DO YOU NEED TO KNOW?

“Does this look like eczema on my skin?”

Start with What Eczema Can Look and Feel Like on Black Skin.

“What can I do myself?”

Go to What You Can Do at Home and How to Know When Self-Care Isn't Enough.

“Is this dark or light mark still eczema?”

Read Treating Eczema Without Ignoring Dark and Light Marks.

“My dermatologist recommended a prescription. What should I ask?”

Go to Prescription Treatments: What Do We Know About Black Patients? and If Your Dermatologist Recommends a New Eczema Treatment, Ask 4 Things.

“How do I know whether my treatment is actually working?”

Go to How Do I Know My Treatment Is Working?

“What should I ask at my next appointment?”

Take The 5 Questions to Take to Your Appointment with you

The 3 Things We Should Know

  1. Eczema doesn't always look red on Black skin. It can look violet, purplish-gray, or ashen instead, and can be easy to miss entirely. If we've been waiting to see redness before taking a flare seriously, we may be waiting on a sign our skin won't reliably give.
  2. Moisturizing matters, but it isn't the ceiling. A good moisturizing routine is the foundation of eczema care, but if eczema keeps coming back, disrupts sleep, or isn't improving, that's a sign a prescription treatment may be needed.
  3. It's fair to ask a dermatologist about their experience with skin like ours. How eczema is scored, tracked, and even studied has historically leaned on how it looks on lighter skin. Asking about a clinician's experience with darker skin tones is a reasonable, informed question, not an awkward one.

What Eczema Can Look and Feel Like on Black Skin

Most descriptions of eczema in textbooks, on packaging, and even in doctors' offices center on redness. But on deeper skin tones, the inflammation underneath eczema doesn't always show up as red. It can appear violet, purplish-gray, or ashen instead, and can be genuinely harder to see against our natural skin tone 2. That doesn't mean it's milder; it means the usual visual cue is unreliable.

Because of this, it helps to pay attention to what we can feel and observe beyond color, i.e., swelling, warmth, tenderness, small bumps, rough or thickened patches, scaling, and, most reliably, itching that is getting worse rather than better. Black patients with eczema are also more likely to have prominent follicular involvement (small, bumpy, goosebump-like changes around the hairs), extra creases on the palms, lines under the eyes (called Dennie-Morgan lines), and darkening of the skin around the eyes 3. Chronic scratching and inflammation can also thicken the skin over time, a process called lichenification, which on Black skin often looks like a leathery, darkened patch rather than a red, raised one.

Throughout this guide, when we mention changes to watch for, we mean changes in color, swelling, warmth, tenderness, bumps, scaling, or worsening itching, not simply redness.

Why Eczema Can Be Missed or Underestimated in Us

Part of the problem starts with how often eczema is even recognized. Eczema is diagnosed in an estimated 19.3% of Black children, yet once it’s found, it is frequently scored as less severe than it is 4.

Medical textbooks have historically underrepresented dark skin. In an analysis of 4,146 images across four leading medical textbooks, just 4.5% depicted dark skin tones 5. That gap means many clinicians are trained on a narrower visual picture than the patients they treat in real life. The tools doctors use to score how severe eczema is, were also largely developed and validated using redness as a core marker, which can make eczema on Black skin look less severe on paper than it feels 2.

Delays compound this. At one major children's hospital, Black infants with eczema waited a median of three and a half months to see a dermatologist after being referred, compared with no wait at all for many white infants, and were far more likely to end up in the emergency room for eczema care in their first year. 6. And much of what's known about eczema, its biology, its triggers, and which treatments work, comes from research where Black patients have historically been underrepresented, a theme that comes up again in the treatment section below 7.

The systems built to recognize and measure eczema were not built with our skin as the reference point, and knowing that can help us advocate for ourselves more confidently and know when to see a licensed dermatology professional with experience with skin like ours.

Why Is This Happening?

Eczema comes from several things working together, not one single cause.

Your skin barrier. Eczema skin loses moisture more easily than normal skin, and that lets irritants and allergens in. If a parent or sibling has eczema, asthma, or seasonal allergies, our own risk is higher, since these conditions often run together and share genetic underpinnings 2. Genetic research specifically in African American populations has identified gene variants associated with eczema risk 8.

Your immune system. Eczema involves an overactive immune response in the skin, driven largely by proteins called cytokines 9. A bacterium called Staphylococcus aureus, or staph, is found on eczema-affected skin far more often than on healthy skin, colonizing an estimated 90% of eczema-affected patches, and it appears to actively worsen inflammation and drive itching 10,11. An imbalanced skin microbiome, i.e., the community of bacteria living on our skin, is a marker of active eczema. 12. We come back to this when we talk about treatments below.

Your environment. Air pollution, chemical exposure, humidity, and allergen exposure can all trigger or worsen flares. 2,7,13

Your biology isn't the whole story. Where we live and how easily we can get to a dermatologist affects how quickly eczema gets diagnosed and properly treated 7. Some ancestry-linked genetic variation may also affect how the body responds to certain medications, including corticosteroids, though this area of research is still developing 14.

What You Can Do at Home

Good daily habits won't cure eczema, but they reduce how often and how severely it flares.

  • Keep showers short and lukewarm, not hot. Hot water strips natural oils and worsens barrier damage.
  • Use a gentle, fragrance-free cleanser rather than regular soap, which can be drying.
  • Pat skin dry and moisturize within a few minutes, while skin is still slightly damp, to help lock in moisture. Thick creams and ointments generally work better than thin lotions.
  • Pay attention to your environment. Dry climates, seasonal changes, hard water, harsh soaps, and certain rough fabrics can all worsen flares for some people, so notice what seems to affect yours.
  • Keep a simple trigger diary. Note new products, fabrics, foods, stress, or weather changes around the time flares start. Patterns can often emerge after a few weeks.
  • Avoid scratching when you can. Scratching feels relieving in the moment but damages the skin barrier further and can introduce bacteria. Keeping nails short or not scratching, and using cold compresses or towels on itchy areas, can help in the moment.

How to Know When Self-Care Isn't Enough

Moisturizer and gentle cleansing are the foundation of eczema care, not the finish line. They calm day-to-day symptoms, but they cannot resolve a flare that has become infected, has disrupted your sleep for weeks, or keeps returning despite consistent care. Consider reaching out to a dermatologist if any of the following show up:

  • Symptoms that persist for more than two to four weeks despite consistent moisturizing and gentle skin care
  • Eczema that disrupts your sleep
  • Flares that keep coming back
  • Signs of possible skin infection: increased warmth, oozing, pain, or fever
  • Rash that is spreading quickly, becoming more painful, or covering noticeably more area within a few days
  • Significant or spreading dark or light patches left behind after a flare

Any one of these is a reasonable reason to get evaluated. There is no need to wait until eczema feels unbearable.

Treating Eczema Without Ignoring Dark and Light Marks

Successfully treating the itching and inflammation is not the same as treating the pigment changes eczema can leave behind. Post-inflammatory hyperpigmentation (dark marks left after inflammation) is extremely common after eczema flares on deeper skin tones, because melanocytes, the cells that produce pigment, are especially reactive to inflammation in darker skin 15. Less commonly, eczema can also leave behind hypopigmentation, or lighter patches 2. These marks can take weeks to months to fade, and for many Black patients, they are a bigger day-to-day quality-of-life concern than the itching itself 16.

Why Treating the Flare Early Matters for Our Skin

The longer active inflammation lingers, the more pigment change it tends to leave behind. This is one of the clearest reasons not to wait it out once we notice changes in color, swelling, warmth, tenderness, bumps, scaling, or worsening itching. Early, adequate treatment of the eczema itself is one of the best tools available for limiting how much dark or light marking is left behind afterward.

WeSeeColor® Takeaway: A dark mark can linger for weeks to months after the underlying eczema is fully calm, so its presence alone does not mean your treatment failed. But if a mark has not started fading at all after a couple of months, or appears to be spreading rather than shrinking, ask a dermatologist whether it is active eczema, post-inflammatory hyperpigmentation, hypopigmentation, or some combination. The answer changes what, if anything, needs additional treatment.

Bleach Baths: Something to Discuss With Your Healthcare Provider

We may have heard of diluted bleach baths as a home remedy for eczema. It helps to be clear about what they can and cannot do. Dilute bleach baths are sometimes recommended for certain people with eczema, particularly when recurrent skin infections or more severe disease are a concern 17. This is not something WeSeeColor® recommends trying without guidance from a licensed dermatologist or other medical provider first. Bleach baths use regular household bleach at a very specific, low dilution, and used incorrectly can irritate or dry out the skin further. Ask a dermatologist or other medical provider whether a bleach bath is appropriate for your eczema and skin before trying one.

The evidence on bleach baths is genuinely mixed. A review pooling ten clinical trials (307 participants total) found bleach baths modestly improved eczema severity, by roughly 22% relative to plain water baths, but they were not clearly better than plain water baths alone in most other comparisons 17. This research did not report results broken down by race, so it isn't clear whether bleach baths work the same way on Black skin specifically. Bleach baths do appear to reduce itch and support the skin barrier, though a separate study found they did not meaningfully reduce staph bacteria levels on the skin, so the antimicrobial benefit some people expect from them remains unproven 18. One proposed mechanism is that dilute bleach calms a specific inflammatory pathway in the skin called NF-κB, an effect shown in mouse studies rather than confirmed directly in people with eczema 19.

WeSeeColor® Takeaway: If a provider recommends a bleach bath, ask exactly what concentration, frequency, and duration they recommend for your skin. This is general reference information, not personalized instruction.

Should I Buy an Eczema Product Because It Says “Microbiome Friendly”?

We may see moisturizers marketed as "prebiotic," "probiotic," or "microbiome-friendly," often with claims about rebalancing the bacteria on our skin 20. There is emerging, genuinely interesting research in this area. But don't assume the words "prebiotic," "probiotic," or "microbiome friendly" mean a product will treat your eczema. These terms reflect real but early science, and the marketing on skincare packaging often runs ahead of what has been proven 21.

WeSeeColor® Takeaway: If you want to try a microbiome-friendly product, think of it as a possible addition to your routine, not a replacement for moisturizer, prescribed treatment, or a dermatologist visit when you need one.

Prescription Treatments: What Do We Know About Black Patients?

IF YOUR DERMATOLOGIST RECOMMENDS A NEW ECZEMA TREATMENT, ASK 4 THINGS

  1. What is this supposed to improve: itching, flares, skin texture, pigment changes, or all of these?
  2. How long should I use it before deciding whether it is working?
  3. What do we know about how it worked in Black patients?
  4. What side effects or skin changes should I watch for on my skin tone?

Many eczema treatments are proven to work overall. What's less often discussed is how many Black patients were included in the studies that proved it, and whether the treatment was specifically shown to work in skin like ours. Below is treatment-by-treatment context to help ask sharper questions at the next visit.

Topical Corticosteroids

The oldest and most widely used eczema treatment, topical steroids, reduce inflammation quickly and are available in a range of strengths. They are generally used for a limited time because of real risks with prolonged use, including skin atrophy or thinning, cracks or fissures, and pigment changes 22, including hypopigmentation in Black skin 2. There is also concern about systemic side effects with heavy or prolonged use, including type 2 diabetes and adrenal gland suppression 23. A recent review of long-term topical steroid safety suggested the risk of atrophy might not be as severe as once thought, but notably found no studies, in children or adults, that had specifically tracked skin color changes from topical steroid use, meaning this is a real, largely unstudied gap rather than a settled question 24.

For extremely severe flares, a short course of oral corticosteroids (pill or liquid) is sometimes used, but only briefly. Stopping them can trigger a severe rebound flare, and international eczema experts have cautioned that this risk, along with their broader side-effect profile, limits their use compared with topical steroids used over time 25. Oral corticosteroids are usually reserved for eczema that is very severe or widespread, making topical treatment alone insufficient; when rapid symptom control is needed, e.g., a severe flare with intense inflammation and itching; or they can be used as a short-term bridge while other longer-term treatments are being started 25.

Do not use steroids on your face without specific instruction from a dermatologist familiar with treating Black skin. Misuse of topical steroids on the face has been linked to steroid-induced rosacea, acne-like breakouts, and visible surface blood vessels (spider veins), problems that can be severe and hard to reverse 26.

What Do We Know About Black Patients?

Topical corticosteroids have been used for decades across all skin tones and remain a first-line treatment. However, they were not typically studied with the kind of race-specific breakdown that newer drugs now report, and the pigment-change question above is a clear example. Most of what we know about their use in Black patients comes from broad clinical experience rather than dedicated subgroup trial data.

WeSeeColor® Takeaway: Steroid creams remain an important treatment for eczema flares, but strength, location, and duration matter. Ask exactly where to use yours, how often, for how long, and what skin changes should make you stop and contact your dermatologist. Because pigment changes and skin thinning on darker skin tones have not been well studied, finding a dermatologist experienced in treating Black skin matters here more than usual.

Calcineurin Inhibitors (Pimecrolimus/Elidel, Tacrolimus/Protopic)

These non-steroid topical medications work by blocking calcineurin, an enzyme inside, which reduces eczema inflammation. Because they don't carry the same atrophy risk as steroids, they're often used on the head, neck, and skin folds, areas where long-term steroid use is riskier. Pimecrolimus is approved for mild-to-moderate eczema in people 2 and older, for use on any affected skin surface. Tacrolimus is approved for moderate-to-severe eczema in people 2 and older and is typically used as a second-line option.

What Do We Know About Black Patients?

Pimecrolimus's approval studies included 403 pediatric patients (ages 2–17), 29% of whom were African American 27. Tacrolimus's combined pediatric-and-adult approval studies (351 pediatric and 632 adult patients) included 27% Black patients, and the drug's label notes that the efficacy difference between its two strengths was particularly evident in Black adults, alongside two other subgroups: patients with more severe disease and those with more extensive body surface area affected 28. Across combined international studies, tacrolimus ointment has shown success rates above 80% in both adult and pediatric patients 29.

WeSeeColor® Takeaway: If your eczema is on your head, neck, or skin folds, ask whether a nonsteroid option like this could reduce how often you need repeated steroid use in those areas. Black patients had meaningful representation in the approval studies for both of these medications, which is reassuring.

Phosphodiesterase 4 (PDE4) Inhibitors

Crisaborole (Eucrisa)

A non-steroid topical ointment approved for mild-to-moderate eczema.

What Do We Know About Black Patients?

In the main studies, 424 of 1,522 participants were Black/African American, and crisaborole generally helped Black patients more than the inactive ointment, but the studies were not large enough to prove exactly how much benefit Black patients got on their own. In Black patients, 32.1% vs 24.6% met the strict main improvement goal, 49.7% vs 33.7% reached clear or almost clear skin by day 29, and patients on crisaborole also tended to improve faster overall. The most common side effect was application-site pain (2.8%, or 8 of 283; across the phase 3 trials overall, treatment-related side effects were uncommon and usually mild to moderate 30,31.

WeSeeColor® Takeaway: Crisaborole generally improved the signs and symptoms of eczema in Black patients, with real efficacy and safety data specific to Black patients, though the studies weren’t large enough to determine the exact size of that benefit. If your dermatologist recommends Eucrisa, ask what improvement you should realistically expect and how long to try it before deciding whether it is working.

Roflumilast (Zoryve)

A once-daily topical cream that works by blocking an enzyme called PDE4, which helps calm the inflammatory signals involved in eczema. It's approved at a 0.15% strength for ages 6 and up, and at a lower 0.05% strength for ages 2 to 5, for mild-to-moderate eczema.

What Do We Know About Black Patients?

About 20% of participants across the two pivotal trials were Black or African American 32. In a separate analysis focused on Black patients, 25.8% achieved treatment success, meaning clear or almost-clear skin with at least a two-grade improvement, at four weeks, compared with 11.5% on the vehicle (inactive) cream, and about 31% saw meaningful itch improvement compared with 21% on vehicle 33.

WeSeeColor® Takeaway: We have real Black-specific efficacy data for Zoryve, which is useful. If it is being considered for you, ask your dermatologist what improvement you should expect by four weeks and what the next step is if you do not see it.

Ruxolitinib (Opzelura)

A topical JAK-inhibitor cream that works by blocking JAK1 and JAK2, two enzymes involved in inflammation, calming the eczema response. It's approved for mild-to-moderate eczema in people 12 and older, for short-term, non-continuous use, and is also notable for being studied separately for treating pigment loss in other skin conditions.

What Do We Know About Black Patients?

Ruxolitinib cream significantly improved eczema severity and itch in Black patients, with 38.1% of Black patients achieving clear or almost clear skin versus 11.5% on vehicle at 8 weeks 34. A dedicated long-term study combining two phase 3 trials looked specifically in Black or African American patients, confirming sustained disease control 35. In a facial eczema trial where 44.2% of participants were Black, ruxolitinib was well tolerated with application-site reactions at only 1.9% 36. Across all trials, Black patients comprised roughly 20–25% of enrolled participants, and efficacy benefits were consistent regardless of race 34,37,38. The most common side effects were mild upper respiratory infections, and serious adverse events were not reported in Black patients 39,40.

WeSeeColor® Takeaway: If Opzelura is being considered, ask how you should apply it, and what changes in your skin you should watch for.

Tapinarof (Vtama)

A once-daily, steroid-free topical cream that works as an aryl hydrocarbon receptor agonist, a mechanism that helps calm skin inflammation and support the skin barrier. Its FDA label doesn't restrict it by severity and covers ages 2 and up, though the clinical trials used for approval specifically enrolled patients with moderate-to-severe eczema.

What Do We Know About Black Patients?

Black or African American participants made up roughly 26–35% of the two pivotal trials (ADORING trials) used for approval, i.e., 813 adults and children combined. These trials included approximately 50% of patients with skin of color based on self-identified race or investigator-assessed skin type, and more than half of all trial participants had the darkest skin tones. 41,42,43. In a separate analysis focused specifically on participants with skin of color, 43–47% of Black patients achieved clear or almost-clear skin, and 49–55% of Black patients achieved at least 75% improvement in eczema severity, both meaningfully higher than the vehicle cream alone 43. A related analysis by race and skin tones found broadly similar results 44. People with skin of color comprise a diverse range of individuals from a large number of racial and ethnic backgrounds that may be distinct or heterogeneous, and more research may be needed on responses to therapy in some of these groups. 43,44 However, this is one of the stronger Black-specific efficacy datasets among newer topical eczema treatments.

The original trials were only 8 weeks long, but in a long-term extension study of 728 patients (ADORING 3) who continued to take tapinarof cream (1%) as continuous or intermittent therapy for up to 48 weeks. 47% of enrollees had skin of color; 30% overall were Black or African American; and overall, 51.9% achieved fully clear skin at least once during this time. Additionally, 81.6% of all patients reached clear or almost-clear skin at least once, and patients stayed treatment-free for an average of 79.8 days between applications. The cream was generally well tolerated over this longer period, with the most common side effects being folliculitis (inflammation of hair follicles [12.1%]), an upper respiratory infection (6.9%), and nasal congestion (6.9%) 45.

WeSeeColor® Takeaway: Black patients were well represented in the Vtama studies, so we have more information about how this treatment performs in skin like ours than we do for many eczema treatments. If your dermatologist recommends it, ask why it is a good choice for your eczema, what improvement you should expect, and what side effects should make you contact them.

Abrocitinib (Cibinqo) and Upadacitinib (Rinvoq)

Oral JAK-inhibitor pills, the same JAK-inhibitor class described above, in pill rather than cream form, for moderate-to-severe eczema, typically used when topical treatments aren't enough.

What Do We Know About Black Patients?

For Black patients with moderate-to-severe eczema, Upadacitinib specifically analyzed 112 Black or African American patients, 35% (15 mg) and 58% (30 mg) achieved at least 90% skin clearance (EASI-90) by week 16, while 26% and 39% had little-to-no itch, and no new safety concerns were seen through 140 weeks 46. Longer term, many of these Black or African American patients stayed well controlled, with 92% of them on 15 mg reaching that same EASI-90 threshold and 75% reporting little-to-no itch at week 140 46.

The other oral JAK-inhibitor, Abrocitinib also worked better than placebo in Black patients, but the Black subgroup was smaller at 83 patients, and the published race-specific results are less detailed 47. In that Black subgroup, the 100 mg and 200 mg doses performed similarly.

Overall, both medicines appear effective in Black patients, but the race-specific evidence is limited. Upadacitinib currently has more direct and longer-term safety and efficacy data in Black patients 46,47. Both drugs have been associated with serious but not common risks.

Both JAK inhibitors carry an FDA black box warning for serious risks, including severe infections, cancer, blood clots, strokes, and heart attacks 48,49. The risks are generally low but higher in those over 65 years of age or have a prior history of these risks. Despite these risks, both drugs are generally described as well tolerated with mostly mild-to-moderate adverse events 50.

WeSeeColor® Takeaway: These medications can work for Black patients, but they also carry important safety warnings. If one is recommended, ask: Why is this treatment appropriate for me? What are my personal risk factors? What should I watch for? What monitoring will I need?

Dupilumab (Dupixent)

This is an injectable biologic (given every 2 weeks), a medication engineered to target one specific part of the immune system rather than suppressing it broadly the way older drugs do. It is currently one of the most widely prescribed advanced eczema treatments.

What Do We Know About Black Patients?

Pooled across its three major approval trials (2,058 patients), only about 6% (128) were Black or African American. A dedicated analysis of this subgroup of 112 Black patients found dupilumab significantly improved eczema severity, itch, and quality of life; results appeared broadly consistent with those seen in white and Asian participants, though the study wasn't designed to formally test for differences between racial groups 51. In pediatric Black patients, overall safety was consistent with the known dupilumab profile 52.

WeSeeColor® Takeaway: This treatment has Black-specific efficacy data behind it, which is reassuring, but Black patients still made up a small share of the people studied relative to how common eczema is in our community. Ask your dermatologist how to administer dupilumab and how they will track whether it is working for your specific skin.

WeSeeColor® Takeaway Research Spotlight: A Study That Focused On Us

Lebrikizumab (Ebglyss)

This is an injectable biologic (administered every 2 weeks), and the subject of the ADmirable trial, one of the only major eczema studies to focus specifically on patients with skin of color from the start, rather than including them as a small slice of a mostly white study population. Of the 90 people enrolled, 77.8% identified as Black or African American, and every participant had medium-to-deep skin tones 53.

What Do We Know About Black Patients?

By 24 weeks, 78.4% of participants achieved at least 75% improvement in eczema severity. That included 95% had the deepest skin tone category. At the start of the study, more than half of participants (57.8%) had noticeable dark marks (hyperpigmentation); by 24 weeks, nearly two-thirds (64.4%) saw those marks improve, and about a quarter (24.4%) saw their skin tone return to match their surrounding unaffected skin. Lichenification (leathery, thickened skin from chronic scratching) improved 72–79% across body regions by week 24 54. Side effects were mostly mild; 32.2% of participants had some treatment-related side effect 53, 2.2% had a severe one, and there were no serious adverse events reported.

This was an open-label study, meaning there was no comparison group or placebo, so the comparative effectiveness of other systemic treatments, such as dupilumab, upadacitinib, or abrocitinib, in Black skin can only be inferred. No placebo to compare to means we cannot dismiss the possibility of a placebo effect (i.e., patients benefit just from believing the drug or placebo will work) or the natural ebb and flow of the disease (eczema).

WeSeeColor® Takeaway

This treatment has unusually strong evidence from a study centered on people with skin of color. If your dermatologist recommends an injectable treatment, ask why this one is appropriate for you, how it is given, what improvement you should expect, how your progress will be measured, and what side effects you should watch for.

Phototherapy

Supervised light therapy, typically using narrowband UVB, used for moderate eczema that hasn't responded well to topical treatment.

What Do We Know About Black Patients?

A comprehensive review of 32 phototherapy trials (1,219 participants total) found it may improve eczema symptoms, but only two of those trials included patients with the deepest skin tones (Fitzpatrick types V and VI), and the review cautioned that overall evidence quality across trials is limited 55.

WeSeeColor® Takeaway Phototherapy, especially narrowband UVB, appears to help eczema, but there is very little dedicated evidence for how well it works in Black skin. Because more pigmented skin generally needs higher UVB doses for the same benefit, ask whether your dosing is being adjusted for your skin tone rather than a one-size-fits-all schedule. Some types, particularly PUVA, can cause a reaction that shows up 48 to 96 hours after treatment rather than right away, so don't assume a reaction days later is unrelated to a recent session 55. If phototherapy is a consideration, discuss risks, benefits, and dosing with a licensed dermatologist experienced with treating Black skin.

How Do I Know My Treatment Is Working?

Because color-based cues aren't always reliable, it helps to track a broader set of signs over the weeks after starting a new treatment:

  • Is my itching less intense or less frequent?
  • Am I scratching less, especially at night?
  • Am I sleeping better?
  • Are new patches appearing less often?
  • Does my skin feel less rough, thick, cracked, or scaly?
  • Are flares becoming less frequent overall?
  • Am I going longer between needing rescue treatment (like a steroid burst)?

A “yes” to most of these is a good sign, even if a dark or light mark is still visible. A mark can remain for weeks to months after the eczema itself has genuinely improved, so it's worth asking a dermatologist whether what's still showing is active eczema or simply the pigment left behind by inflammation that has already resolved.

The 5 Questions to Take to Your Appointment

Bring this list, or a photo of it, to your next visit:

  1. Is what I am seeing active eczema, pigment changes left behind by eczema, or both?
  2. How will we know whether treatment is working on my skin?
  3. What do we know about this treatment in Black patients?
  4. What side effects or skin changes should I watch for?
  5. If this doesn't work, when should I contact you, and what would we consider next?

More Questions You May Want to Ask

  • Does my eczema look different because of my skin tone?
  • Could this treatment lighten or darken my skin?
  • Do you regularly diagnose and treat eczema in patients with my skin tone?
  • If my eczema seems linked to a specific trigger, like a food, fabric, or product, should I have allergy testing done, or would seeing an allergist help?
  • Would your treatment recommendation change if I did not have deeply pigmented skin?
  • Could this treatment interact with other medications or supplements I take?

WeSeeColor® BOTTOM LINE

Eczema on Black skin may not look like the red rashes you've been taught to expect. Pay attention to itching, texture, swelling, scaling, warmth, and changes in color. Protect your skin barrier, but don't keep trying new products if your eczema keeps returning, disrupts your sleep, or isn't improving.

And remember: the dark or light mark left behind isn't always active eczema. Ask what you're seeing before trying to treat the color.

If you need prescription treatment, ask what we know about that treatment in Black patients, how you will know whether it is working on your skin, and when you should come back if it isn't.

“Considering a product for eczema-prone skin? Submit it to WeSeeColor® for an evaluation so you can better understand its ingredients and claims before deciding whether it belongs in your routine.”

This article is for education and is not medical advice. Talk with your doctor or a dermatologist experienced in Black skin about your specific situation. Explore more research summaries written for us across WeSeeColor, and submit a product for our team to evaluate.

References

  1. Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911
  2. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340-357. doi:10.1111/exd.13514
  3. Sangha AM. Dermatological conditions in skin of color: Managing atopic dermatitis. J Clin Aesthet Dermatol. 2021;14(3 Suppl 1):S20-S22.
  4. Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449-455. doi:10.1016/j.anai.2018.11.015
  5. Louie P, Wilkes R. Representations of race and skin tone in medical textbook imagery. Soc Sci Med. 2018;202:38-42. doi:10.1016/j.socscimed.2018.02.023
  6. Servattalab SE, Lee M, Hlobik M, Song H, Huang JT. Examining racial and ethnic disparities in diagnosis and access to care in infantile atopic dermatitis in the USA: A retrospective cohort study. Br J Dermatol. 2025;192(1):144-151. doi:10.1093/bjd/ljae322
  7. Croce EA, Levy ML, Adamson AS, Matsui EC. Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. J Allergy Clin Immunol. 2021;148(5):1104-1111. doi:10.1016/j.jaci.2021.09.015
  8. Gautam Y, Satish L, Ramirez S, et al. Joint genotype and ancestry analysis identify novel loci associated with atopic dermatitis in African American population. HGG Adv. 2024;5(4):100350. doi:10.1016/j.xhgg.2024.100350
  9. Trier AM, Kim BS. Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies. Br J Dermatol. 2023;188(6):698-708. doi:10.1093/bjd/ljac016
  10. Deng L, Costa F, Blake KJ, et al. S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis. Cell. 2023;186(24):5375-5393.e25. doi:10.1016/j.cell.2023.10.019
  11. Al Kindi A, Williams H, Matsuda K, et al. Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33. J Allergy Clin Immunol. 2021;147(4):1354-1368.e3. doi:10.1016/j.jaci.2020.09.023
  12. Bjerre RD, Bandier J, Skov L, Engstrand L, Johansen JD. The role of the skin microbiome in atopic dermatitis: A systematic review. Br J Dermatol. 2017;177(5):1272-1278. doi:10.1111/bjd.15390
  13. Kantor R, Silverberg JI. Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol. 2017;13(1):15-26. doi:10.1080/1744666X.2016.1212660
  14. Daya M, Barnes KC. African American ancestry contribution to asthma and atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):456-462. doi:10.1016/j.anai.2019.02.009
  15. Markiewicz E, Karaman-Jurukovska N, Mammone T, Idowu OC. Post-inflammatory hyperpigmentation in dark skin: Molecular mechanism and skincare implications. Clin Cosmet Investig Dermatol. 2022;15:2555-2565. doi:10.2147/CCID.S385162
  16. Dumbuya H, Kindred C, Frey CN, Draelos ZD. Atopic dermatitis skincare and impact on quality of life for patients with skin of color. J Drugs Dermatol. 2024;23(3 Suppl 2):SF395747s6-SF395747s11. PMID 38443136.
  17. Bakaa L, Pernica JM, Couban RJ, et al. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE. Ann Allergy Asthma Immunol. 2022;128(6):660-668.e9. doi:10.1016/j.anai.2022.03.024
  18. Stolarczyk A, Perez-Nazario N, Knowlden SA, et al. Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis. Arch Dermatol Res. 2023;315(10):2883-2892. doi:10.1007/s00403-023-02723-1
  19. Leung TH, Zhang LF, Wang J, Ning S, Knox SJ, Kim SK. Topical hypochlorite ameliorates NF-κB-mediated skin diseases in mice. J Clin Invest. 2013;123(12):5361-5370. doi:10.1172/JCI70895
  20. Gueniche A, Valois A, Kerob D, Rasmont V, Nielsen M. A combination of Vitreoscilla filiformis extract and Vichy volcanic mineralizing water strengthens the skin defenses and skin barrier. J Eur Acad Dermatol Venereol. 2022;36(Suppl 2):16-25. doi:10.1111/jdv.17786
  21. Draelos ZD. The role of 'biotics in skincare. Dermatology Times. 2020;41(5). https://www.dermatologytimes.com/view/role-biotics-skincare
  22. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15. doi:10.1016/j.jaad.2005.01.010
  23. Burshtein J, Chovatiya R, Golant A, Zakria D, Shah M, Lio P, Lebwohl M. Risks of topical corticosteroid therapy and role for advanced targeted topical treatments for inflammatory skin diseases: An expert consensus panel. Dermatol Online J. 2025;31(1). doi:10.5070/D331164978
  24. Harvey J, Lax SJ, Lowe A, et al. The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. Skin Health Dis. 2023;3(5):e268. doi:10.1002/ski2.268
  25. Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768-775. doi:10.1111/bjd.15928
  26. Manchanda K, Mohanty S, Rohatgi PC. Misuse of topical corticosteroids over face: A clinical study. Indian Dermatol Online J. 2017;8(3):186-191. doi:10.4103/idoj.IDOJ_535_15
  27. U.S. Food and Drug Administration. Elidel (pimecrolimus) cream, 1% [Prescribing information]. 2003. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21302scp004_elidel_lbl.pdf
  28. U.S. Food and Drug Administration. Protopic (tacrolimus) ointment [Prescribing information]. 2000. https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/50777lbl.pdf
  29. Kim KH, Kono T. Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas. Int J Dermatol. 2011;50(9):1153-1161. doi:10.1111/j.1365-4632.2011.04881.x
  30. U.S. Food and Drug Administration. Drug trials snapshot: Eucrisa. 2016. https://web.archive.org/web/20250323140951id_/https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-eucrisa
  31. Callender VD, Alexis AF, Stein Gold LF, et al. Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups. Am J Clin Dermatol. 2019;20(5):711-723. doi:10.1007/s40257-019-00450-w
  32. Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024;160(11):1161-1170. doi:10.1001/jamadermatol.2024.3121
  33. Arcutis Biotherapeutics, Inc. New data shows ZORYVE (roflumilast) cream 0.15% provided consistent improvement of atopic dermatitis in individuals with diverse skin types [Press release]. 2024. https://www.arcutis.com/new-data-shows-zoryve-roflumilast-cream-0-15-provided-consistent-improvement-of-atopic-dermatitis-in-individuals-with-diverse-skin-types/
  34. Papp K, Szepietowski JC, Kircik L, et al. Efficacy of ruxolitinib cream by baseline patient demographics: Pooled subgroup analysis from two randomized phase 3 studies [Abstract]. J Am Acad Dermatol. 2021;85(3):AB149. doi:10.1016/j.jaad.2021.06.609
  35. Eichenfield LF, Stein Gold LF, Chiesa Fuxench ZC, Venturanza ME, Ren H, Brar KK. Long-term safety and disease control of ruxolitinib cream among Black or African American patients with atopic dermatitis: Pooled results from 2 phase 3 studies [Conference abstract]. J Am Acad Dermatol. 2022;87(3):AB180. https://scholarlycommons.henryford.com/dermatology_mtgabstracts/207/
  36. Chiesa Fuxench ZC, Lai Z, Kuo YT, Nawaz H, Cotliar J. Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: Results from a decentralized, randomized phase 2 clinical trial. J Dermatolog Treat. 2025;36(1):2480744. doi:10.1080/09546634.2025.2480744
  37. Simpson EL, Augustin M, Thaçi D, et al. Ruxolitinib cream monotherapy improved symptoms and quality of life in adults and adolescents with mild-to-moderate atopic dermatitis: Patient-reported outcomes from two phase III studies. Am J Clin Dermatol. 2025;26(1):121-137. doi:10.1007/s40257-024-00901-z
  38. Mohney LA, Singh R, Feldman SR. Review of ruxolitinib in the treatment of atopic dermatitis. Ann Pharmacother. 2023;57(2):207-216. doi:10.1177/10600280221103282
  39. Joyce JC, Hong HC, Siri DD, Toth D, Kallender H, Kuo YT, Stefani-Hunyady D, Papp KA. Safety and tolerability of ruxolitinib cream in adolescents with mild-to-moderate atopic dermatitis: Results from a 1-year, phase III, open-label study. Am J Clin Dermatol. 2026 (ahead of print). doi:10.1007/s40257-026-01043-0
  40. Eichenfield LF, Simpson EL, Papp K, et al. Efficacy, safety, and long-term disease control of ruxolitinib cream among adolescents with atopic dermatitis: Pooled results from two randomized phase 3 studies. Am J Clin Dermatol. 2024;25(4):669-683. doi:10.1007/s40257-024-00855-2
  41. Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457-465. doi:10.1016/j.jaad.2024.05.023
  42. Dermavant Sciences, Inc. Dermavant presents new data on treatment of patients with skin of color from ADORING 1 and 2 phase 3 pivotal trials of VTAMA (tapinarof) cream, 1%, in adults and children 2 years of age and older with atopic dermatitis at the 2024 AAD Annual Meeting [Press release]. BioSpace. 2024. https://www.biospace.com/dermavant-presents-new-data-on-treatment-of-patients-with-skin-of-color-from-adoring-1-and-2-phase-3-pivotal-trials-of-vtama-tapinarof-cream-1-percent-in-adults-and-children-2-years-of-age-and-older-with-atopic-dermatitis-at-the-2024-aad-annual-meeting
  43. Alexis AF, Kircik L, Chovatiya R, et al. Tapinarof cream for adults and children with atopic dermatitis—Efficacy by race and Fitzpatrick skin type in two phase 3 randomized clinical trials. Dermatol Ther (Heidelb). 2025;15(9):2667-2682. doi:10.1007/s13555-025-01489-w
  44. Alexis AF, Kircik L, Chovatiya R, et al. Tapinarof cream 1% once daily is efficacious for the treatment of atopic dermatitis in patients with skin of color down to 2 years of age in two pivotal phase 3 trials [Abstract 670]. Br J Dermatol. 2024;191(Suppl 2):ljae266.044. doi:10.1093/bjd/ljae266.044
  45. Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol. 2025;93(3):707-714. doi:10.1016/j.jaad.2025.05.1391
  46. Alexis A, Friedman A, Elbuluk N, et al. Skin clearance and itch relief in Black or African American patients with moderate-to-severe atopic dermatitis treated with upadacitinib: 140-week outcomes from integrated phase 3 Measure Up [Abstract]. SKIN J Cutan Med. 2025;9(6):s615.
  47. Alexis A, Silverberg JI, et al. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by baseline patient demographics: Post hoc analysis of a phase 3 trial. Ann Allergy Asthma Immunol. 2024;132(3):383-389.e3. doi:10.1016/j.anai.2023.11.002
  48. Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: Data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25(4):639-654. doi:10.1007/s40257-024-00869-w
  49. Wang M, Gao X, Zhang L. Efficacy and safety of Janus kinase selective inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis. Allergy Asthma Proc. 2025;46(2):88-97. doi:10.2500/aap.2025.46.240113
  50. Gao Q, Zhao Y, Zhang J. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9(6):e16704. doi:10.1016/j.heliyon.2023.e16704
  51. Alexis AF, Rendon M, Silverberg JI, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J Drugs Dermatol. 2019;18(8):804-813.
  52. Alexis A, Heath C, Desai SR, et al. Dupilumab demonstrates improvements in biomarker levels across racial subgroups in pediatric patients with moderate-to-severe atopic dermatitis. Rev Fr Allergol. 2023;63(3):103413. doi:10.1016/j.reval.2023.103413
  53. Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: Results from the phase IIIb, open-label ADmirable study. Am J Clin Dermatol. 2025;26(5):803-817. doi:10.1007/s40257-025-00970-8
  54. Kindred C, Chovatiya R, Waibel J, et al. Lebrikizumab treatment improves lichenification and other clinical signs of atopic dermatitis in adults and adolescents with moderate-to-severe AD and skin of color [Abstract]. SKIN J Cutan Med. 2025;9(6):s625. doi:10.25251/0262jz84
  55. Musters AH, Mashayekhi S, Harvey J, et al. Phototherapy for atopic eczema. Cochrane Database Syst Rev. 2021;2021(10):CD013870. doi:10.1002/14651858.CD013870.pub2